恆瑞醫藥(600276.SH):HRS-8829注射用濃溶液獲得藥物臨牀試驗批準通知書
格隆匯6月27日丨恆瑞醫藥(600276.SH)公佈,子公司北京盛迪醫藥有限公司收到國家藥品監督管理局覈準簽發關於HRS-8829注射用濃溶液的《藥物臨牀試驗批準通知書》,將於近期開展臨牀試驗。HRS-8829爲小分子藥物,擬用於治療急性缺血性卒中。臨牀前研究顯示,HRS-8829可以顯著降低神經功能評分、減少腦梗死和腦水腫、抑制炎症因子表達、改善腦神經元數量減少和抑制腦細胞凋亡,有望爲急性缺血性卒中患者提供新的治療方法。截至目前,HRS-8829注射用濃溶液累計研發投入約974萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.